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Abstract
Background: Methodological research into the design, conduct, analysis and reporting of trials is essential to optimise the
process. UK specialists in the field have established a set of top priorities in aid of this research. These priorities, however,
may not be reflected in the needs of similar research in low- to middle-income countries (LMICs) with different
healthcare provision, resources and research infrastructure. The aim of the study was to identify the top priorities for
methodological research in LMICs to inform further research and ultimately to improve clinical trials in these regions.
Methods: An online, two-round survey was conducted from December 2016 to April 2017 amongst researchers and
methodologists working on trials in LMICs. The first round required participants to suggest between three and six
topics which they felt were priorities for trial methodological research in LMICs. The second round invited participants
to grade the importance of a compulsory list of topics suggested by four or more individuals, and an optional list of
the remaining topics.
Findings: Rounds 1 and 2 were completed by 412 and 314 participants, respectively. A wide spread of years of
experience, discipline, current country of residence, origin of trials training and area of involvement in trials was
reported. The topics deemed most important for methodological research were: choosing appropriate outcomes to
measure and training of research staff.
Conclusion: By presenting these top priorities we have the foundations of a global health trials methodological research
agenda which we hope will foster future research in specific areas in order to increase and improve trials in LMICs.
Keywords: Trials methodology, Priority setting, Global health
Background
Clinical trials are widely recognised as the ‘gold standard’
for estimating treatment effects [1]; however, they are
often costly and time-consuming [2]. Methodological
research into the design, conduct, analysis and reporting
of trials aims to optimise trials so as to yield reliable
results in a cost- and time-effective manner. In a previ-
ous study the most important methodology research
topics for trials within the UK were identified, by the key
stakeholder group of directors of UK Clinical Research
Centre (UKCRC)-registered clinical trials units (CTUs),
as methods to boost recruitment, choosing appropriate
outcomes to measure and methods to minimise attrition
[3]. However, due to economic, political and cultural
differences, it cannot be assumed that priorities for trial
method research in the UK mirror either those in other
high-income countries or, importantly, those in low- to
middle-income countries (LMICs).
LMICs are under-represented within trials method-
ology research. The 2013 World Health Report encour-
aged LMICs to become the generators and not just
recipients of research data in order for relevant research,
according to region-specific health needs and priorities,
to result in improvements in public health outcomes [4].
There is a need for methodological research in LMICs
to ensure that relevant issues are identified and
* Correspondence: a.rosala-hallas@liverpool.ac.uk
1Clinical Trials Research Centre, Biostatistics, University of Liverpool, Liverpool,
UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rosala-Hallas et al. Trials  (2018) 19:48 
DOI 10.1186/s13063-018-2440-y
communicated to healthcare workers in these regions so
that they might optimise future designs for trials.
The aim of the study was to identify the top priorities
for methodological research according to researchers
and methodologists working in LMIC trials.
Methods
A two-round online survey was conducted from December
2016 to April 2017, targeting researchers who had designed,
conducted or analysed trials in LMICs. An invitation letter,
describing the scope of the study and providing a hyperlink
to the survey, was circulated amongst members of the
Global Health Network, the European and Developing
countries Clinical Trials Partnership (EDCTP) and other
networks identified via the authors. The registry Clinical-
Trials.gov was used to search for trials currently open to
recruitment in LMICs. Researchers involved in these trials
who had provided an email address were contacted.
Countries were deemed as LMICs according to the Organ-
isation for Economic Co-operation and Development
(OECD) Development Assistance Committee (DAC) list
of Official Development Assistance (ODA) recipients in
2016 [5].
The survey was conducted in English and translations
of the invitation letter in French, Spanish and Chinese
were also disseminated in order to help the targeted
participants understand the scope of the study. These
translations were either back-translated or checked by a
second individual to ensure that no information was lost
or changed during the translation process.
In round 1, an initial eligibility question identified
health professionals and methodologists who had clinical
trial experience in LMIC settings. Participants were
asked about their professional background, current
Fig. 1 Flow chart showing participation throughout the survey
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country of residence and invited to provide between
three and six topics that they believed should be prior-
ities for trials methodology research in LMICs. Trials
methodology research was defined as research investi-
gating the methods, practices and procedures that are
used for the design, conduct, analysis, interpretation and
Table 1 Professional background and demographic details for
survey completers
Round 1
N = 412
Round 2
N = 314
Years of experience working in clinical trials
Mean (SD) 7.67 (7.02) 7.89 (7.14)
Median (IQR) 5 (3, 10) 6 (3, 10)
Range 1, 45 1, 50
Participant disciplines
Clinical disciplines 268 (65%) 196 (62%)
Public health 59 (14%) 47 (15%)
Infectious diseases 57 (14%) 40 (13%)
General medicine 48 (12%) 27 (9%)
Paediatrics 24 (6%) 14 (4%)
General surgery 17 (4%) 13 (4%)
Nursing 9 (2%) 7 (2%)
Obstetrics 8 (2%) 12 (4%)
Primary care 8 (2%) 7 (2%)
Psychiatry 8 (2%) 3 (1%)
Dentistry 5 (1%) 2 (1%)
Oncology 5 (1%) 4 (1%)
Physiotherapy 3 (1%) 3 (1%)
Cardiology 2 (<1%) 1 (< 1%)
Gynaecology 2 (< 1%) 1 (< 1%)
Haematology 2 (< 1%) 2 (1%)
Neurosurgery 2 (< 1%) 1 (< 1%)
Anaesthesia 1 (< 1%) 1 (< 1%)
Dermatology 1 (< 1%) 1 (< 1%)
Ear, nose and throat diseases 1 (< 1%) 1 (< 1%)
Neurology 1 (< 1%) 0 (0%)
Nutrition 1 (< 1%) 2 (1%)
Orthopaedics and trauma 1 (< 1%) 6 (2%)
Pneumology 1 (< 1%) 0 (0%)
Rheumatology 1 (< 1%) 1 (< 1%)
Urology 1 (< 1%) 0 (0%)
Research methods disciplines 85 (21%) 61 (19%)
Trials management 37 (9%) 19 (6%)
Statistics 19 (5%) 16 (5%)
Data management 13 (3%) 10 (3%)
Epidemiology 7 (2%) 8 (3%)
Ethics 3 (1%) 2 (1%)
Quality assurance 2 (< 1%) 2 (1%)
Clinical research 2 (< 1%) 2 (1%)
Health economics 1 (< 1%) 1 (< 1%)
Information systems 1 (< 1%) 0 (0%)
Mathematics 0 (0%) 1 (< 1%)
Laboratory science disciplines 37 (9%) 44 (14%)
Table 1 Professional background and demographic details for
survey completers (Continued)
Round 1
N = 412
Round 2
N = 314
Biomedical sciences 12 (3%) 27 (9%)
Pharmacy 12 (3%) 10 (3%)
Parasitology 4 (1%) 5 (2%)
Immunology 3 (1%) 0 (0%)
Biology 2 (< 1%) 0 (0%)
Microbiology 2 (< 1%) 1 (< 1%)
Biotechnology 1 (< 1%) 1 (< 1%)
Chemistry 1 (< 1%) 0 (0%)
Other disciplines 22 (5%) 13 (4%)
Health management (administration) 6 (1%) 3 (1%)
Social sciences 6 (1%) 4 (1%)
Community engagement 3 (1%) 1 (< 1%)
Complementary medicine 3 (1%) 2 (1%)
Pharmacology 2 (< 1%) 1 (< 1%)
Medical devices 1 (< 1%) 0 (0%)
Pharmacogenomics 1 (< 1%) 0 (0%)
Global health 0 (0%) 1 (< 1%)
Environmental heath 0 (0%) 1 (< 1%)
Origin of trial experience
In a low- to middle-income country
(LMIC) only
250 (61%) 196 (63%)
In both a LMIC and a high-income
country (HIC)
100 (24%) 76 (24%)
In a HIC only 62 (15%) 42 (13%)
Involvement in clinical trials
Design 240 (58%) 174 (55%)
Conduct 361 (88%) 267 (85%)
Analysis 213 (53%) 171 (54%)
Reporting 257 (62%) 200 (64%)
Current residence by continent
Africa 210 (51%) 171 (54%)
Asia 82 (20%) 55 (18%)
Europe 64 (16%) 41 (13%)
South America 32 (8%) 30 (10%)
North America 23 (6%) 16 (5%)
Australia 1 (< 1%) 1 (< 1%)
SD standard deviation, IQR interquartile range
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reporting of clinical trials. Topics were categorised and
reviewed by the Steering Committee, and those deemed
not applicable or beyond the scope of the survey were
excluded. A primary list of topics identified by four or
more respondents was created in order to decrease par-
ticipant burden in the second round thereby increasing
the likely response rate, and the remaining topics were
included in a secondary list. In order to aid comparison
between the UK and LMIC priorities, topics in the pri-
mary list for the UK survey which were not suggested in
the current survey were also added to the secondary list.
The hyperlink to round 2 of the survey was circulated to
those who provided an email address in round 1. These
first-round participants were sent weekly reminders to
complete the survey via email to maximise the response
rate. Round-2 participants were again required to provide
information about their professional backgrounds and
then to assign the topics in each list a score, using the
GRADE guidelines scale [6] in order to identify the more
important research topics. Scores of 1 to 3 indicated that
the topic was not important, 4 to 6 important but not
critical, and 7 to 9 critically important. So as to reduce
participant burden, assigning of grades to topics in the
primary list was compulsory for completion but optional
for topics in the secondary list. As an incentive, those who
completed both rounds of the survey were included in a
prize draw to win travel to, and accommodation at, the
joint International Clinical Trials Methodology Conference
and Society of Clinical Trials 2017 Conference in Liverpool,
UK. Completion of the survey was deemed consent to
participate.
Results
Round 1 of the survey was accessed by 826 people; 124
(15%) indicated no previous involvement in clinical trials
and thus did not continue. Of the remaining partici-
pants, 85/702 (12%) participants did not answer any fur-
ther questions after indicating involvement in trials, 205/
702 (29%) completed questions about their professional
backgrounds only and 412/702 (59%) completed round 1
by providing at least one priority topic (Fig. 1).
Table 1 shows the demographic and professional charac-
teristics of the completers of round 1 of the survey. The
number of years of experience working in clinical trials for
those who completed round 1 ranged from 1 to 45 years,
with a mean (standard deviation) of 7.7 (7.0) years.
Approximately half of the participants (210/412, 51%)
reported to be currently residing in a country in Africa
and over 80 different countries were represented. A
variety of clinical disciplines was represented, the major-
ity being public health (14%), infectious diseases (14%)
and general medicine (12%); however, researchers with
trial-specific roles (trial management, data management
and statistics) also participated.
Over 60% of participants received their clinical trial
training in a LMIC only. Most researchers reported
involvement in the conduct of trials (88%) with over
50% having experience in each of the design, analysis
and reporting stages.
The 205 participants who gave information about their
professional backgrounds but did not complete the
survey were similar to those who completed the survey
(Additional file 1: Table S1).
Those who completed round 1 and provided an email
address (378/412, 92%) were contacted to participate in
round 2. A total of 314/378 (83%) participated. The
characteristics of the subgroup that completed round 2
were similar to those of the whole group (Table 1).
A total of 1620 topics were identified, of which 703
(43%) were deemed not applicable due to being too
vague or beyond the scope of the study (raw data show-
ing the classifications can be made available on request).
The remaining 917 topics were categorised and divided
into two lists. The primary list was limited to the 27
topics suggested by four or more participants (Fig. 2).
The secondary list comprised the 55 remaining topics
suggested and two identified as a priority from the previ-
ous UK study but not identified in the current study,
giving a total of 57 topics (Fig. 3).
Over 50% of the topics which were scored as critically
important by 80% or more responders on both LMIC
lists 1 and 2 were around issues in trial conduct, includ-
ing: training of research staff, strategies for adverse event
reporting, methods for data capture, methods for data
management, informed consent processes, methods for
trial monitoring, consent in emergency settings, methods
for ensuring better consent for samples, methods for
electronic data capture, risk assessments, accessibility to
health services in rural areas.
The top priority for further methodological research
for trials in LMICs is appropriate choice of outcomes to
measure. Some examples of topics falling within choos-
ing appropriate outcomes to measure, given by respon-
dents, were: developing the correct objectives for the
study, standardising outcome sets and identifying
patient-focussed endpoints. The second top priority is
methods related to training of research staff; for ex-
ample, finding cost-effective and purposeful methods to
train research staff and the use of blended learning in-
corporating new technologies.
Choice of appropriate outcomes to measure, methods
for the conduct of pragmatic trials and calculating sample
size all appeared in the top 10 most important items in
both the LMIC and UK priority lists [2].
Discussion
Many of the topics deemed most important to LMIC
researchers were related to trial conduct as opposed to
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trial design or analysis. This could stem from resource
issues and may indeed highlight the requirement for
capacity development, stressing the need for cost and
time-effective methods. The majority (85%) of round-2
participants have been involved in the conduct of trials
and, therefore, issues around trial conduct could be
more relevant to them.
The priority most commonly graded as critically import-
ant, choosing appropriate outcomes to measure, was also
a priority identified in the UK study and there is ongoing
work on this through the Core Outcome Measures in
Effectiveness Trials (COMET) Initiative [7]. Launched in
January 2010, COMET aims to optimise the choice of out-
comes by providing a standardised set of outcomes (core
outcome sets) for specific disease areas and/or popula-
tions. Up until December 2015 only 44/248 (18%) com-
pleted core outcome set studies involved participants
from LMICs. Given that choosing appropriate outcomes
Fig. 2 Topics identified by four or more as priorities, ordered by importance ranks
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to measure was the topic most important to researchers
in LMICs, there is a need for greater involvement of these
countries in the development of core outcome sets.
It is also important to LMIC researchers to prioritise
research into methods for training research staff. One
example of implementing and reviewing a training
programme is within the Good Health Research Practice
(GHRP) initiative which aims to train researchers in
applying Good Clinical Practice (GCP). A short course
using an experimental learning cycle, the process of
conceptualising, applying, acting and reflecting, was piloted
between 2014 and 2015 in LMICs [8]. New methods to
improve the training programme were identified during
the pilot phase and incorporated into future programmes.
Research should now be done to find methods for training
which are available and effective in LMICs.
Fig. 3 Topics identified by fewer than four as priorities, ordered by importance ranks
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The results suggest that, although some research
priorities seem to be applicable to both LMICs and
high-income countries, differences may exist between
these broad regions. For example, in the UK there was a
greater emphasis on recruitment and retention, yet these
topics did not appear in the top 10 most commonly
graded as critically important by LMIC researchers,
potentially due to the fact that involvement in trials
guarantees access to more personalised healthcare
which, outside of a trial setting, could be limited in
LMICs due to capacity issues or the intervention not
being available outside the trial [9, 10].
Although snowball sampling methods were used to dis-
seminate the survey, which sometimes raises concerns with
respect to representativeness, information on demographic
details and professional backgrounds of the participants in-
dicated that a wide spread of disciplines and countries were
involved, thus strengthening the applicability of the results.
One limitation to note was that participants were
researchers and, therefore, there was no patient and
public involvement (PPI); this was due to pragmatic
reasons, since it would be difficult to identify partici-
pants from trials in LMICs; however, it would be useful
to obtain their views. It is important that further
research based on these results includes PPI so as to
conduct research into methods which are also relevant
and applicable to patients and the public.
Another limitation of the survey was around the
number of topics suggested which were deemed not
applicable or beyond the survey scope. Those deemed
not applicable were often too vague; for example, ‘trial
logistics’, ‘statistical analysis’ and ‘improving trial
efficiency’ or to do with a specific disease area; for
example, ’HIV’, ‘malaria’; a full list of responses and
groupings are provided as a Additional file 2. Partici-
pants had space to report the reason for suggesting
each topic and where uncertainties to do with applic-
ability arose, this information was used to aid
decision-making. Some topics deemed not applicable
may have been due to language barriers; however,
translations of the invitation letters should have mini-
mised this risk. The invitation letter was translated to
French and checked by speakers who were fluent, al-
though not native. The Chinese and Spanish versions
were both translated and checked by native speakers.
The survey, itself, was not translated.
Furthermore, it is possible that the 29% of people who
completed background information in round 1 but did
not provide any priorities perhaps did not believe there
were any priorities for methodological research. How-
ever, due to the ‘free-text’ nature of the survey it is as-
sumed that if participants completed background
questions, and felt strongly that there were no priorities,
a comment would have been left to indicate this.
Although LMICs share the same limitation of re-
source issues, it should also be noted that the specific
needs of different regions within LMICs could vary;
for this reason a wide spread of countries was in-
cluded in the survey. An extension of this work; however,
could target the priorities of specific countries or regions
within LMICs.
A variety of disciplines was represented in the survey
but it could also be the case that priorities vary depending
on respondent affiliations (for example, private vs public).
These findings provide a preliminary step towards
achieving the foundations of a global health trials meth-
odological agenda which we hope will foster method-
ology research in specific areas in order to increase and
improve trials in LMICs.
Conclusions
Choosing appropriate outcomes to measure and
methods of training research staff were the top priorities
for trialists in LMICs.
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